Jeongin Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeongin Lee has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Jihun Song
Korea University College of Medicine
2 shared publications- Seogsong Jeong
Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Republic of Korea
2 shared publications Yihyun Kim
Korea University College of Medicine
2 shared publicationsEun Seok Kang
Department of Biomedical Informatics, Korea University College of Medicine , Seoul 02841
1 shared publication- Eun Seok Kang
Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea
1 shared publication Hwamin Lee
Department of Biomedical Informatics, Korea University College of Medicine , Seoul 02841
1 shared publication
Latest Publications
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Risk Factors for Coronary Heart Disease and Stroke Among Older Adults With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Nationwide Cohort Study
Background: Older adults with metabolic dysfunction–associated steatotic liver disease have elevated cardiovascular disease (CVD) risk, yet conventional models, such as the Framingham Risk Score, rely on linear assumptions and were developed for younger populations. Nonlinear machine learning approaches may improve risk prediction in this high‐risk group. Methods: Using Korean National Health Insurance Service data, this population‐based cohort study followed up 67 575 adults, aged ≥65 years, with metabolic dysfunction–associated steatotic liver disease (assessed 2009–2010) for incident CVD, coronary heart disease, and stroke from 2011 to 2019. Cox proportional hazards (CoxPH) models identified time‐to‐event predictors, whereas an extreme gradient boosting (XGBoost)–based survival model explored nonlinear associations and predicted 9‐year CVD risk. Results: Both CoxPH and XGBoost models outperformed the Framingham Risk Score, with CoxPH showing slightly better discrimination than XGBoost in the validation sets. The 2 models identified broadly similar leading predictors. For coronary heart disease, both identified Charlson comorbidity index, antiplatelet agent use, and serum creatinine among the most important predictors. In the CoxPH model, the Charlson comorbidity index had the highest explained relative risk (0.031), and the XGBoost model also ranked Charlson comorbidity index first by Shapley Additive Explanations value (0.159). For stroke, both models identified age, Charlson comorbidity index, and antiplatelet agent use as the top 3 predictors, with age ranked first (explained relative risk, 0.065; Shapley Additive Explanations, 0.239). Similar findings were observed for total CVD. Conclusions: In older adults with metabolic dysfunction–associated steatotic liver disease, CoxPH and survival XGBoost showed similar predictive performance and identified key predictors not emphasized in traditional models, like the Framingham Risk Score. These findings underscore limitations of applying younger‐population–based tools to older adults with metabolic dysfunction–associated steatotic liver disease and support the development of tailored CVD risk models.
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Risk Factors for Coronary Heart Disease and Stroke Among Older Adults With Metabolic Dysfunction–Associated Steatotic Liver Disease: A Nationwide Cohort Study
Background: Older adults with metabolic dysfunction–associated steatotic liver disease have elevated cardiovascular disease (CVD) risk, yet conventional models, such as the Framingham Risk Score, rely on linear assumptions and were developed for younger populations. Nonlinear machine learning approaches may improve risk prediction in this high‐risk group. Methods: Using Korean National Health Insurance Service data, this population‐based cohort study followed up 67 575 adults, aged ≥65 years, with metabolic dysfunction–associated steatotic liver disease (assessed 2009–2010) for incident CVD, coronary heart disease, and stroke from 2011 to 2019. Cox proportional hazards (CoxPH) models identified time‐to‐event predictors, whereas an extreme gradient boosting (XGBoost)–based survival model explored nonlinear associations and predicted 9‐year CVD risk. Results: Both CoxPH and XGBoost models outperformed the Framingham Risk Score, with CoxPH showing slightly better discrimination than XGBoost in the validation sets. The 2 models identified broadly similar leading predictors. For coronary heart disease, both identified Charlson comorbidity index, antiplatelet agent use, and serum creatinine among the most important predictors. In the CoxPH model, the Charlson comorbidity index had the highest explained relative risk (0.031), and the XGBoost model also ranked Charlson comorbidity index first by Shapley Additive Explanations value (0.159). For stroke, both models identified age, Charlson comorbidity index, and antiplatelet agent use as the top 3 predictors, with age ranked first (explained relative risk, 0.065; Shapley Additive Explanations, 0.239). Similar findings were observed for total CVD. Conclusions: In older adults with metabolic dysfunction–associated steatotic liver disease, CoxPH and survival XGBoost showed similar predictive performance and identified key predictors not emphasized in traditional models, like the Framingham Risk Score. These findings underscore limitations of applying younger‐population–based tools to older adults with metabolic dysfunction–associated steatotic liver disease and support the development of tailored CVD risk models.
- 10 February 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (2) , 260-268
Coexistence of atrial fibrillation and metabolic dysfunction-associated steatotic liver disease as a high-risk overlap for incident heart failure in older adults
Older adults with atrial fibrillation (AFib) face a high risk of heart failure (HF). We investigated whether the coexistence of AFib and metabolic dysfunction–associated steatotic liver disease (MASLD) and its subtypes, including MASLD with increased alcohol intake (MetALD) and alcoholic liver disease (ALD), further increases the risk of HF. Patients (aged ≥60 years) with AFib diagnosed between 2002 and 2010 were collected from the Korean National Health Insurance Service database. MASLD status was determined during 2009–2010 [fatty liver index (FLI) ≥30]. The association between MASLD and incident HF was assessed using Fine–Gray subdistribution hazard models. Participants were followed from 1 January 2011, until the occurrence of HF, death, or 31 December 2019, whichever came first. Among 7543 older adults with AFib, 3168 had MASLD, 259 had MetALD, and 159 had ALD. The presence of MASLD (subdistribution hazard ratio, 1.22; 95% CI, 1.10–1.35, P < .001), MetALD (1.36; 1.05–1.76, P = .019), and ALD (1.42; 1.03–1.97, P = .034) was associated with a higher risk of incident HF. In restricted cubic spline analyses, significant dose–response relationships were observed for both the FLI and daily alcohol consumption, each of which was associated with increased HF risk among patients with AFib. Coexistence of AFib and MASLD identifies a high-risk overlap state for incident HF in older adults. These findings highlight the importance of recognizing inflammatory liver dysfunction driven by metabolic and alcohol-related factors as a potential amplifier of HF risk in older adults with AFib. In a cohort of 7543 older adults with AFib, the coexistence of SLD was associated with an increased risk of incident HF compared with non-SLD reference participants. Relative to non-SLD, adjusted HF risk was elevated in MASLD (aSHR 1.22, 95% CI 1.10–1.35), MetALD (aSHR 1.36, 95% CI 1.05–1.76), and ALD (aSHR 1.42, 95% CI 1.03–1.97). Dose-response patterns were observed across fatty liver index, alcohol intake, and fasting serum glucose, supporting that metabolic and alcohol-related liver dysfunction jointly amplifies HF risk in older adults with AFib.
- 10 February 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (2) , 260-268
Coexistence of atrial fibrillation and metabolic dysfunction-associated steatotic liver disease as a high-risk overlap for incident heart failure in older adults
Older adults with atrial fibrillation (AFib) face a high risk of heart failure (HF). We investigated whether the coexistence of AFib and metabolic dysfunction–associated steatotic liver disease (MASLD) and its subtypes, including MASLD with increased alcohol intake (MetALD) and alcoholic liver disease (ALD), further increases the risk of HF. Patients (aged ≥60 years) with AFib diagnosed between 2002 and 2010 were collected from the Korean National Health Insurance Service database. MASLD status was determined during 2009–2010 [fatty liver index (FLI) ≥30]. The association between MASLD and incident HF was assessed using Fine–Gray subdistribution hazard models. Participants were followed from 1 January 2011, until the occurrence of HF, death, or 31 December 2019, whichever came first. Among 7543 older adults with AFib, 3168 had MASLD, 259 had MetALD, and 159 had ALD. The presence of MASLD (subdistribution hazard ratio, 1.22; 95% CI, 1.10–1.35, P < .001), MetALD (1.36; 1.05–1.76, P = .019), and ALD (1.42; 1.03–1.97, P = .034) was associated with a higher risk of incident HF. In restricted cubic spline analyses, significant dose–response relationships were observed for both the FLI and daily alcohol consumption, each of which was associated with increased HF risk among patients with AFib. Coexistence of AFib and MASLD identifies a high-risk overlap state for incident HF in older adults. These findings highlight the importance of recognizing inflammatory liver dysfunction driven by metabolic and alcohol-related factors as a potential amplifier of HF risk in older adults with AFib. In a cohort of 7543 older adults with AFib, the coexistence of SLD was associated with an increased risk of incident HF compared with non-SLD reference participants. Relative to non-SLD, adjusted HF risk was elevated in MASLD (aSHR 1.22, 95% CI 1.10–1.35), MetALD (aSHR 1.36, 95% CI 1.05–1.76), and ALD (aSHR 1.42, 95% CI 1.03–1.97). Dose-response patterns were observed across fatty liver index, alcohol intake, and fasting serum glucose, supporting that metabolic and alcohol-related liver dysfunction jointly amplifies HF risk in older adults with AFib.